Cures 2.0 May Get Fast Tracked Due To COVID-19
Executive Summary
Follow-up bill to the 21st Century Cures Act looks to be more focused on reimbursement and delivery than the 2016 law, which centered on speeding drug development and approval. The bill's architects are working to get some of their provisions, including those around antibiotics, attached to the next COVID-19 relief legislation.
You may also be interested in...
Real-World Evidence Uptake Is “Silver Lining” Of COVID-19 Response, USFDA’s Abernethy Says
The coronavirus pandemic highlights the work that is still needed on real-world evidence, agency's principal deputy commissioner says.
House Would Slow US FDA Budget Authority Increases In FY 2021
After two years of significant growth in non-user fee funds, House appropriators offer FDA a more modest increase for FY 2021.
Cures II Wish List: Reconsidering Accelerated Approval?
Richard Pazdur wants the oncology community to take a fresh look at US FDA’s expedited review programs. One big question: should there be fewer of them?
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: